BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Business

  Seagen and LAVA Therapeutics Ink $700M+ Deal for EGFR Solid Tumor Platform

  Seagen and LAVA Therapeutics inked a licensing deal for LAVA’s Gammabody platform for solid tumors, which can potentially exceed $700 million.

  September 26, 2022

   · 

  2 min read

   · 

  Mark Terry
• 

  Drug Development

  Clinical Catch-Up: Equillium, 9 Meters, ABVC and More

  Equillium, 9 Meters Biopharma and ABVC Biopharma have something to say about lupus, short bowel syndrome and ADHD.

  September 26, 2022

   · 

  6 min read

   · 

  Vanessa Doctor, RN
• 

  Increasing Biologics Manufacturing Efficiency and Lowering Costs with QbD

  Quality by design principles, when fully optimized, can decouple much of the process from the molecule itself, leading to significant efficiencies.

  September 26, 2022

   · 

  6 min read

   · 

  Gail Dutton
• 

  Business

  MassBioEd Aims to Solve Genetown’s Skilled Labor Dilemma while Biogen Clears Space

  MassBioEd partners with developers in Boston to train and employ more workers in a burgeoning Genetown life sciences industry desperate for skilled labor. Meanwhile, Biogen clears real-estate space.

  September 26, 2022

   · 

  2 min read

   · 

  Paul Elias
• 

  Drug Development

  Lynparza Ovarian Cancer Withdrawal Latest in Series of PARP Inhibitor Setbacks

  The announcement follows a subgroup analysis of the Phase III SOLO3 trial which showed patients treated with Lynparza saw a 33% greater risk of death than controls who received standard chemotherapy.

  September 26, 2022

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Daiichi Sankyo’s Ezharmia Becomes First EZH1/2 Inhibitor for Blood Cancer

  Daiichi Sankyo won approval in Japan for Ezharmia, making it the first dual inhibitor of EZH1 and EZH2 to receive regulatory approval for ATL.

  September 26, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Policy

  ODAC Votes Against Safety Profile of Secura Bio’s P13K Inhibitor (Updated)

  In an 8-4 vote, the FDA’s Oncologic Drugs Advisory Committee Roster voted against the benefit-risk profile of Secura Bio’s P13K inhibitor Copiktra (duvelisib).

  September 26, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Lipocine Shifts Pipeline Focus to CNS Disorders (Updated)

  Lipocine will undergo a strategic realignment and focus its drug development program on developing a pipeline of differentiated products for central nervous system disorders.

  September 26, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Career Advice

  A Comprehensive Guide to Success for Women in the Life Sciences

  BioSpace spoke with Saundra Pelletier, CEO of Evofem Biosciences, to discuss the realities of being a woman in the life sciences and find out the career moves that propelled her forward.

  September 26, 2022

   · 

  6 min read

   · 

  Abbey Glasure
• 

  Policy

  Rubric Rejects Mereo’s Latest Offer in Ongoing Proxy Battle

  In the ongoing proxy battle between London-based Mereo BioPharma Group and Rubric Capital Management, Mereo outlined the outcome of the most recent negotiations, which Rubric rejected.

  September 26, 2022

   · 

  2 min read

   · 

  Mark Terry